Brian F. Chapin, M.D. on the Uptake of PSMA PET in Prostate Imaging

Video

The approval of Blue Earth Diagnostics' Posluma (flotufolastat F 18) is a significant step forward for PSMA PET imaging, but will it actually help improve patient outcomes?

This content originally appeared on our sister site, Urology Times.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Prostate cancer imaging is having its moment in the spotlight, with numerous advances in imaging agents for positron emission tomography slated to help improve diagnostics in a disease that's rife with recurrence.

      The most recent news comes from Blue Earth Diagnostics, whose radioactive imaging agent Posluma (flotufolastat F 18) was recently approved in May 2023 for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

      While improved imaging will certainly move the needle on diagnosis, it's yet to be seen how this will ultimately impact patient outcomes.

      In an interview with our sister site, Urology Times, Brian F. Chapin, M.D., associate professor of urology at the University of Texas MD Anderson Cancer Center in Houston, spoke about the potential impact of PSMA PET and some of the challenges the clinical community is facing in the wake of these advances.

      Click here for more of the latest research on prostate imaging.

      Recent Videos
      Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
      Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
      What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
      What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
      Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
      Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
      Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
      Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
      Current and Emerging Legislative Priorities for Radiology in 2025
      Current and Emerging Legislative Priorities for Radiology in 2025
      How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
      How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
      A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
      A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
      How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
      How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
      A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
      A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
      Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
      Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
      Related Content
      Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging

      Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging

      Jeff Hall
      May 7th 2025
      Article

      For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.

      The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET

      The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET

      Jeff Hall
      March 18th 2025
      Podcast

      In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

      PSMA PET/CT Study Shows Mixed Results with Single Metastasis-Directed Radiotherapy for Oligometastatic PCa

      PSMA PET/CT Study Shows Mixed Results with Single Metastasis-Directed Radiotherapy for Oligometastatic PCa

      Jeff Hall
      May 5th 2025
      Article

      While PSMA PET/CT revealed an 87 percent local remission rate after metastasis-directed radiotherapy for oligometastatic prostate cancer in a new study, researchers also found that 80 percent of patients had biochemical progression at a median 32-month follow-up.

      FDA Clears AI-Powered Prostate Volume Measurement for Handheld Ultrasound

      FDA Clears AI-Powered Prostate Volume Measurement for Handheld Ultrasound

      Jeff Hall
      April 25th 2025
      Article

      Offering expedited calculation of prostate volume, Clarius Prostate AI is reportedly the first AI-enabled prostate measurement tool to garner FDA clearance for use with handheld ultrasound.

      New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection

      New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection

      Jeff Hall
      April 15th 2025
      Article

      Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.

      Self-Interpretation of Imaging by Non-Radiologists Accounts for 43.5 Percent of Medicare Imaging Claims

      Self-Interpretation of Imaging by Non-Radiologists Accounts for 43.5 Percent of Medicare Imaging Claims

      Jeff Hall
      April 3rd 2025
      Article

      In a review of over 1,630,000 office-based non-breast imaging Medicare fee-for-service (FFS) claims from 2022, researchers found that 39.5 percent of nuclear medicine imaging were interpreted by ordering clinicians.

      © 2025 MJH Life Sciences

      All rights reserved.